Insiders who reported open-market trades in the last 12 months at the companies John Raymond Murphy files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Quang X. Pham - $423K in CVKD purchases and sales in the last 12 months
Matthew K. Szot - $120K in CVKD purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
John Raymond Murphy is a corporate insider, tracked as Director of Cadrenal Therapeutics, Inc. (CVKD). InsiderAlpha holds 5 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has John Raymond Murphy submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
Has John Raymond Murphy been buying or selling stock?
Recorded transactions: 0 open-market purchases and 3 open-market sales ($795K) across all tracked filings.
John Raymond Murphy is Director of Cadrenal Therapeutics, Inc. (CVKD). 5 SEC Form 4 filings on record going back to 2025, most recently on 13 October 2026. Most recent open-market trade: sold $230K of ORLY on 20 May 2026. Lifetime open-market sales: $795K.
Recent transactions
5
The latest 5 SEC Form 4 transactions reported by John Raymond Murphy.
InsiderAlpha's records for John Raymond Murphy go back to 2025: 5 primary Form 4 filings, an average of 2.5 per year. No recorded transaction carries a Rule 10b5-1 plan flag. An absent flag does not establish whether a transaction was pre-arranged or discretionary.
